A multicenter study assessing the efficacy of various preoperative/pre-transfusion screening methods for blood transmitted disease
10.3760/cma.j.cn114452-20220829-00498
- VernacularTitle:术前/输血前筛查血源性传播疾病风险检测方法比较的多中心研究
- Author:
Junhua HU
1
;
Li QIN
;
Juan LIU
;
Xinghuan MA
;
Qin MENG
;
Peng WANG
;
Jiangcun YANG
;
Rong GUI
;
Chunhong DU
;
Xiying LI
;
Xianping LYU
;
Rong XIA
;
Fenghua LIU
;
Shu SU
;
Jinqi MA
;
Yuan ZHANG
;
Juan CAI
;
Huifang JIN
;
Qi ZHANG
;
Jun ZHANG
;
Rongyi CAO
;
Bing HAN
;
Jiwu GONG
;
Jun ZHOU
Author Information
1. 北京医院输血科 国家老年医学中心 中国医学科学院老年医学研究院，北京 100730
- Keywords:
Communicable disease;
Chemiluminescent immunoassay;
Nucleic acid amplification techniques;
Infections
- From:
Chinese Journal of Laboratory Medicine
2023;46(1):32-37
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This multi-centre study was conducted to assess the efficacy of various preoperative/pre-transfusion screening methods for blood transmitted disease.Methods:From July 2021 to December 2021, plasma samples of patients admitted to 10 hospitals were collected for screening preoperative/pre-transfusion blood transmitted disease. Nucleic acid detection technology was used to detect hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA and human immunodeficiency virus (HIV)(1+2) RNA, and the results were compared with the immuno-serological methods. χ 2 test and Kappa test were used to analyze the efficacy of these two methods. Results:A total of 8 655 valid specimens were collected from 10 hospitals. There was a statistically significant difference in the positive detection rate of HCV between the two methods ( P<0.001). There was no significant difference in the positive detection rate of HBV and HIV assessed by the two methods ( P>0.05), but the number of positive cases detected by HBV DNA and HIV RNA (218 and 4 cases) was significantly higher than the corresponding serological results (216 and 2 cases). At the same time, there were HBV, HCV and HIV immuno-serological omissions by the immuno-serological methods, among which 28 cases were HBsAg negative and HBV DNA positive, 2 cases were HCV antibody negative and HCV RNA positive, and 2 cases were HIV antigen/antibody negative and HIV RNA positive. In addition, in the 66 samples with inconsistent results from the two detection methods, 83.3% (55/66), 68.2% (45/66), 63.6% (42/66) and 62.1% (41/66) of patients aged was>45 years, tumor, surgery and male, respectively. Conclusions:Compared with immuno-serological tests, nucleic acid tests have the advantage in terms of sensitivity on detecting HBV, HCV and HIV infection and could reduce missed detection. The risk of transmission can be reduced by adding HBV, HCV, and HIV nucleic acid tests to preoperative/pre-transfusion immuno-serological tests screening for patients over 45 years of age and tumor patients.
